Literature DB >> 4095670

Plasma histamine concentration during propranolol induced bronchoconstriction.

P W Ind, P J Barnes, M J Brown, C T Dollery.   

Abstract

The mechanism of propranolol induced bronchoconstriction in asthma is uncertain, as airway beta adrenoceptors are not innervated by sympathetic nerves and circulating adrenaline concentrations are not raised. Propranolol 10 mg was infused over 27 minutes in 14 subjects with mild asthma. Peak expiratory flow (PEF) decreased by 80-235 l/min (17-51% of baseline) in nine subjects, who were called "responders," and by less than 50 l/min (12% of baseline) in five "non-responders". These two groups did not differ in baseline ventilatory function or in any clinical characteristic. In "responders" mean PEF had decreased significantly from 440 to 390 l/min after infusion of propranolol 2.1 mg, though the maximum fall in PEF occurred during or within five minutes of the end of the infusion. In nine of the subjects (six "responders" and three "non-responders") the possibility that propranolol induced bronchoconstriction is due to blockade of mast cell beta receptors leading to increased mediator release was examined by measurement of plasma histamine concentration as an index of mast cell degranulation. There was no consistent change in plasma histamine concentration in either group. No evidence of increased mast cell mediator release has been found in association with propranolol induced bronchoconstriction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4095670      PMCID: PMC460222          DOI: 10.1136/thx.40.12.903

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  28 in total

1.  The effect of beta adrenergic blockade on bronchial sensitivity to acetyl-beta-methacholine in normal and allergic rhinitis subjects.

Authors:  R G Townley; S McGeady; A Bewtra
Journal:  J Allergy Clin Immunol       Date:  1976-04       Impact factor: 10.793

2.  The Veterans Administration-Army cooperative study of pulmonary function. I. Clinical spirometry in normal men.

Authors:  R C KORY; R CALLAHAN; H G BOREN; J C SYNER
Journal:  Am J Med       Date:  1961-02       Impact factor: 4.965

3.  Distribution and fate of 54Mn in the monkey: studies of differnnt parts of the central nervous system and other organs.

Authors:  D K Dastur; D K Manghani; K V Raghavendran
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808

4.  Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects.

Authors:  P J Barnes; N B Pride
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

5.  Measurement of plasma histamine in asthma.

Authors:  P W Ind; P J Barnes; M J Brown; R Causon; C T Dollery
Journal:  Clin Allergy       Date:  1983-01

6.  Beta-blocking drugs and airways obstruction.

Authors:  D R Gauld; M C Pain; A R Rubinfeld
Journal:  Med J Aust       Date:  1979-07-28       Impact factor: 7.738

7.  Beta-adrenergic function in airways of healthy and asthmatic subjects.

Authors:  P Gayrard; J Orehek; C Grimaud; J Charpin
Journal:  Thorax       Date:  1975-12       Impact factor: 9.139

8.  Protective effect of disodium cromoglycate on propranolol challenge.

Authors:  G H Koëter; H Meurs; J G de Monchy; K de Vries
Journal:  Allergy       Date:  1982-11       Impact factor: 13.146

9.  Basophil "releasability" in patients with asthma.

Authors:  S R Findlay; L M Lichtenstein
Journal:  Am Rev Respir Dis       Date:  1980-07

10.  A novel double-isotope technique for the enzymatic assay of plasma histamine: application to estimation of mast cell activation assessed by antigen challenge in asthmatics.

Authors:  M J Brown; P W Ind; R Causon; T H Lee
Journal:  J Allergy Clin Immunol       Date:  1982-01       Impact factor: 10.793

View more
  1 in total

1.  Propranolol inhalation challenge in relation to histamine response in children with asthma.

Authors:  J Gerritsen; G H Koëter; L T Vander Weele; K Knol
Journal:  Thorax       Date:  1988-06       Impact factor: 9.139

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.